权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cancer Center Support Grant

癌症中心支持补助金

基本信息

批准号：
10319022
负责人：
Thomas James Lynch
金额：
$ 1009.01万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-01-01 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10319022
关键词：
Alaska Area Biology Cancer Biology Cancer Center Cancer Center Support Grant Cancer Detection Cancer Etiology Carcinogenesis Mechanism Caregivers Catchment Area Cause of Death Cessation of life Child Childhood Clinical Clinical Research Collaborations Communities Comprehensive Cancer Center Computational Biology County Development Diagnosis Diagnostic Discipline Disease Education and Outreach Educational process of instructing Enrollment Ensure Exposure to Faculty Faculty Recruitment Fostering Funding Genomics Goals Grant Health Health Sciences Hematopoietic Stem Cell Transplantation Idaho Immunology Immunotherapeutic agent Individual Institution Intervention Investments Knowledge Laboratories Laboratory Research Leadership Malignant Neoplasms Measures Mentors Mission Molecular Montana Outcome Patients Peer Review Population Research Postdoctoral Fellow Prevention Prevention strategy Primary Prevention Public Health Quality of Care Research Research Infrastructure Research Personnel Research Training Resources Risk Factors Science Secondary Prevention Students Therapeutic Training Training Support Training and Education Translating Translational Research Translations Transplantation Underrepresented Populations United States Universities Washington Work Wyoming anticancer research base cancer care cancer diagnosis cancer therapy carcinogenesis clinical care clinical practice computer studies epigenomics graduate student host neoplasm interaction improved insight inter-institutional interdisciplinary collaboration interest member mortality multidisciplinary next generation outreach pathogen profiles in patients programs synthetic biology targeted treatment therapy development treatment center treatment trial tumor tumor metabolism tumor progression

项目摘要

PROJECT SUMMARY: OVERALL The Fred Hutchinson/University of Washington Cancer Consortium (“the Consortium”) brings together more than 600 members with research interests in basic, clinical and public health sciences related to cancer. The goal of the Consortium is the elimination of cancer as a cause of suffering and death through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration among the partner institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. The Consortium was established in 2002 to build upon the complementary strengths and resources of three partner institutions: the Fred Hutch, which has been an NCI-designated Comprehensive Cancer Center since 1976; the University of Washington, which has significant strength in cancer research, clinical care, and teaching; and Seattle Children’s, the major pediatric academic center in the region. In 2008, the Seattle Cancer Care Alliance, the cancer treatment center founded and equally co-owned by the three founding institutions, was formally added to the cancer center designation. The Consortium’s total funding base (direct dollars) is $242M, of which $117M is peer-reviewed, including $50M from the NCI. During the last grant period, over 170 new faculty members joined the Consortium, adding breadth and depth to our research and clinical capabilities. In the most recent year, we enrolled 1,338 patients onto interventional treatment trials, of which more than 50% were investigator-initiated. The ratio of accruals to newly registered patients was 28%. The Consortium serves a catchment area of 13 counties in western Washington. This equates to the region in which 83 percent of our patients reside. As the only NCI-designated comprehensive cancer center in a five- state region (Washington, Wyoming, Alaska, Montana and Idaho), we not only seek to serve the health needs of the catchment area through research, training, and outreach, but also to ensure high impact throughout the larger region. The Consortium continues to build upon historic strengths in basic cancer biology, immunology and transplantation, pathogen associated malignancies, tumor specific translational research, computational biology and studies of cancer etiology, prevention, and outcomes. The Consortium is well poised to continue its exceptional level of research in these areas. The CCSG continues to have a high impact on the Consortium, fostering new inter-institutional collaborations, strengthening the translational research platform, and intensifying research efforts on problems of the catchment area. Partner institutions contributed nearly $1.2 billion in institutional support during the last project period, including investments in our laboratory and clinical research infrastructure as well as in faculty recruitment and trainee support.

项目总结：总体